Alkermes Plc

Alkermes Plc achieved a new 52-week high of USD 48.30, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a significant stock price increase over the past year, with solid metrics in return on equity and price-to-book ratio, while maintaining a competitive position in the industry.

Alkermes Plc has achieved a new 52-week high, reflecting an impressive 85.7% stock appreciation over the past year, significantly outperforming the S&P 500. With a market capitalization of USD 5,008 million, the company demonstrates effective management and a strong financial position, despite not offering dividends.

Alkermes Plc has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with an impressive one-year growth rate. The company, classified as small-cap, shows effective management through its return on equity and maintains a notable market valuation despite a lack of dividends.

Alkermes Plc has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with an impressive one-year growth. The company, with a market capitalization of USD 5,008 million, showcases a competitive P/E ratio and a notable return on equity, despite a unique capital structure.

Alkermes Plc has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a favorable P/E ratio and a solid return on equity, indicating effective management and profitability.

Alkermes Plc has achieved a new 52-week high of USD 40.78, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 65.11% growth over the past year, with a P/E ratio of 14.00 and a return on equity of 19.54%, emphasizing effective management.

Alkermes Plc, a small-cap pharmaceutical company, has experienced fluctuations in its stock price, currently at $29.72. Technical indicators present a mixed outlook, with varying performance against the S&P 500. The recent evaluation revision emphasizes the complexities of its market position and performance metrics.

Alkermes Plc, a small-cap pharmaceutical company, has experienced stock price fluctuations, currently at $30.99. The company has shown resilience, outperforming the S&P 500 over various time frames, including a notable five-year return of 108.62%. Mixed technical indicators suggest a complex market outlook for the stock.

Alkermes Plc has seen a notable increase in stock performance, gaining 10.58% on September 30, 2025, with an intraday high of USD 30.16. The company has demonstrated resilience compared to the S&P 500, showcasing strong operating profit growth and solid financial metrics despite recent challenges.

Alkermes Plc, a small-cap pharmaceutical company, has seen its stock price rise recently, reflecting market dynamics. The stock has experienced volatility over the past year, with mixed technical indicators suggesting varied trends. Performance comparisons with the S&P 500 show short-term gains but longer-term underperformance.